Abstract. The present study was designed to determine the efficiency and safety of ultrasound (US) and/or US contrast agent microbubbles (MBs) in the delivery of type 2 recombinant adeno-associated virus-delivered transforming growth factor-β2 short hairpin ribonucleic acid encoding the enhanced green fluorescent protein gene (rAAV2-TGFβ2 shRNA-EGFP) and the downregulation of TGFβ2 in rat retinal pigment epithelium (RPE-J) cells. The effects of US and/or MBs on the delivery of rAAV2-EGFP and rAAV2-TGFβ2 shRNA-EGFP were evaluated by fluorescence microscopy and flow cytometry. The potential toxicity of cell viability under various US or MB conditions was assessed by CellTiter 96 ® AQueous One solution cell proliferation assay. The level of TGFβ2 mRNA in RPE-J cells under various conditions was estimated by reverse transcription-quantitative polymerase chain reaction analysis. The results obtained demonstrated that low-intensity US (0.5 W/cm 2 and 30 sec) or SonoVue (MB:cell ratio, 40:1) increased the delivery efficiency of rAAV2-EGFP and rAAV2-TGFβ2 shRNA-EGFP to RPE-J cells, whereas the combination of US with MBs did not further increase but instead decreased rAAV transfection. Under the optimal conditions of rAAV delivery, enhanced TGFβ2 gene silencing with a combination of US or SonoVue with rAAV2-TGFβ2 shRNA resulted in a significant decrease in mRNA levels compared with rAAV2-TGFβ2 shRNA alone. US or SonoVue was used safely to enhance the delivery of rAAV2-TGFβ2 shRNA to RPE-J cells. A combination of the biological (rAAV2-TGFβ2 shRNA) and physical (US or SonoVue) approaches downregulated the mRNA level of TGFβ2 more effectively.
Introduction
Proliferative vitreoretinopathy (PVR) is characterized by the formation of contractile membranes in the vitreal cavity and on both surfaces of the retina. Retinal pigment epithelial (RPE) cells are considered to play a pivotal role in the formation and the contraction of these membranes, and are known to secrete a wide range of growth factors which are significant in the progression of the disease, including transforming growth factor-β (TGFβ), platelet-derived growth factor and fibroblast growth factor (1) . TGFβ2 is considered to be the predominant TGFβ isoform in the posterior segment. TGFβ2 has been identified in membranes excised from patients with PVR by immunohistochemistry. TGFβ2 concentration is elevated in the vitreous of patients with the disease (2, 3) . Therefore, targeting of the TGFβ2 gene with a small interfering RNA (siRNA) in RPE cells has the potential to prevent the development of PVR.
RNA interference (RNAi) is a promising biological strategy for the treatment of diverse diseases; however, the therapeutic application of siRNA has been limited by its instability and poor cellular uptake efficiency (4) . If the siRNA in vivo is to become effective with high efficiency and stability in the long-term, a vector is required. Currently, the virus vector is the main vector applied in RNAi research. Recombinant adeno-associated virus (rAAV), characterized by low immunogenicity and long exogenous gene expression time, is particularly applicable to the gene therapy of ophthalmology. The identification of the rAAV vector of RNAi provides the premise for the enhanced use of RNAi technology to silence related genes in the treatment of ophthalmic diseases (5, 6) . However, the solution to the low infection rate of rAAV has not yet been elucidated (7, 8) . The use of ultrasound (US) and microbubbles (MBs) has been proven to be safe and efficient in various organs. Our previous studies demonstrated that US with MBs enhanced rAAV transfection efficiency in ARPE19 cells (9, 10) . The present study was designed to determine whether US and/or MBs not only facilitate the delivery of rAAV2-enhanced green fluorescent protein (EGFP) but also the downregulation of TGFβ2 combined with rAAV2-TGFβ2 shRNA in rat RPE cells. To the best of our knowledge, only a few studies have been published with regard to US/MBs combined with AAV-mediated RNAi in the sphere of ophthalmology. If successful, such an approach may provide an alternative gene delivery method for RNAi in RPE cell-related diseases.
Materials and methods

rAAV2-EGFP-based transfection in RPE-J cells with US and/or US contrast agent
Cell culture. A rat RPE-J cell line was obtained from the American Type Culture Collection (CRL-2240; ATCC, Rockville, MD, USA). The cells were cultured to 70-80% confluence in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA) supplemented with 4% fetal bovine serum at 37˚C, in 5% CO 2 /95% air. RPE cells were placed onto every other well of a 24-well plate at a concentration of 1x10 5 cells per well prior to infection.
US contrast agent and virus.
SonoVue, a lipid-shelled US contrast agent filled with sulfur hexafluoride gas, composed of ~2x10 8 per ml MBs, and having an average diameter of 2.5-6.0 mm, was purchased from Bracco (Milan, Italy). Perfluoropropane-albumin microspheres, an albumin-shelled US contrast agent filled with perfluoropropane gas, composed of ~5x10 8 per ml MBs, and having an average diameter of 3-4.5 µm, was purchased from Jing Da pharmaceutical Co., Ltd., Hu Nan, China; approval number S20083098). Finally, rAAV2-EGFP [2x10 12 vector genomes per milliliter (vg/ml)] was purchased from Vector Gene Technology Company Ltd. (Beijing, China). A dose of 1x10 4 MOI was used (multiplicity of infection: vector genomes/number of cells).
US exposure protocol. The volume per well was 150 µl when exposed to US and the method of transfection configuration was the same as we previously reported (9) . A therapeutic US device (Topteam 161, Chattanooga Medical Supply, Inc., Chattanooga, TN, USA) was used as previously described (9) . We set the experimental conditions as follows: frequency, 1 MHz; US intensity, 0.5 and 1 W/cm 2 ; duration, 30, 60 and 90 sec; pulse wave with 50% duty cycle; with or without MBs (SonoVue or perfluoropropane-albumin microspheres; MB:cell ratio, 20:1, 40:1 and 60:1). RPE cells were infected by rAAV alone (control) or in combination with US (rAAV+US), SonoVue (rAAV+SonoVue), perfluoropropane-albumin microspheres (rAAV+microsphere) or US-targeted microbubble destruction (UTMD; rAAV+US+SonoVue and rAAV+US+microsphere group; MB:cell ratio, 20:1).
Gene transfer efficiency. Forty-eight hours after rAAV transfection, EGFP expression was observed and photographed using an inverted fluorescence microscopy (Zeiss Axiovert S100, Carl Zeiss, Oberkochen, Germany). The ratio of infected cells was examined by a fluorescence-activated cell sorter (FACS; Epics XL, Beckman Coulter, Miami, FL, USA). Table I ) and control siRNA were designed and synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). To avoid possible off-target effects in the rat, these target sequences had been used to screen Gen-Bank using BLAST. To test siRNAs, RPE-J cells were co-transfected with synthetic siRNAs and Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Finally, the optimal RNAi target sequence (TGFβ2-771) was selected by the expression level of mRNA.
rAAV2-TGFβ2 shRNA-U6-EGFP constructs. rAAV2-TGFβ2
shRNA-U6-EGFP was constructed by Vector Gene Technology Company Ltd. on the basis of the TGFβ2-771 we selected. Transgenes were driven by the U6 promoter. The titer of genome particles was 2.7x10 11 vg/ml. rAAV2-neg-shRNA-U6-EGFP was also constructed by the same company. The titer of genome particles was 4.4x10 11 vg/ml.
US-or SonoVue-mediated rAAV2-TGFβ2
shRNA-EGFP transfected RPE cells. RPE cells were placed into a 12-well plate at a concentration of 1x10 5 cells per well. The method of transfection configuration was the same as described above. The dose of rAAV2-TGFβ2 shRNA-EGFP and rAAV2-negshRNA-EGFP was 5x10 4 MOI.
FACS-examined EGFP expression. rA AV2-TGFβ2
shRNA-EGFP was transfected into RPE cells with US (0.5 W/cm 2 and 30 sec) or SonoVue (MB:cell ratio, 40:1). rAAV2-TGFβ2 shRNA-EGFP transfected alone served as the control. Forty-eight hours after transfection, EGFP expression (ratio of positive cells and mean fluorescence density) was examined by FACS.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis of TGFβ2 gene expression.
The level of TGFβ2 mRNA in RPE-J cells was estimated by RT-qPCR analysis 48 h after rAAV2-TGFβ2 shRNA-EGFP was transfected with US (0.5 W/cm 2 and 30 sec) or SonoVue (MBs:cells, 40:1). RPE-J cells that were not treated were used as a control. To determine the efficiency of gene delivery by a combination of US or SonoVue, the cells transfected with rAAV2-neg-shRNA-EGFP were also collected to measure the mRNA levels 48 h post-transfection. Total RNA was harvested using a TRIzol reagent kit (Invitrogen, Karlsruhe, Germany) and then reverse transcription to synthesize cDNA was achieved using a reverse transcription system (Promega). RT-qPCR was performed with the extracted total RNA using Taq PCR Master mix (Toyobo Co., Ltd., Osaka, Japan). Quantification using the 2 −ΔΔCT analytical method was performed in triplicate with GAPDH used for internal standardization. Oligonucleotide primers used for the analysis of gene expression were purchased from Sangon Co. Ltd. (Shanghai, China), as listed in Table II .
Statistical analysis. All values are expressed as the means ± standard deviation. All cell viability experiments were performed in 12 parallel wells. All transfection experiments were performed in three parallel wells. An identical procedure was followed and repeated three times. One way analysis of variance was used to determine the significance of the differences in multiple comparisons. P<0.05 was considered to indicate a statistically significant difference. The software package used was GraphPad Prism, version 5.0 (GraphPad Software, Inc, La Jolla, CA, USA).
Results
rAAV-based transfection in RPE-J cells with US and/or contrast agent.
Gene transfer by US. The US intensities and exposure times were set at 0.5 and 1 W/cm 2 , and at 30, 60 and 90 sec, respec- Fig. 1D and E) . 
rAAV2-TGFβ2 shRNA-EGFP-based transfection in RPE-J cells with US or SonoVue and TGFβ2 gene silencing evaluation.
Under optimal conditions, both US (0.5 W/cm 2 and 30 sec) and SonoVue (MB:cell ratio, 40:1) significantly enhanced the rAAV2-TGFβ2 shRNA-EGFP ratio of positive cells (P<0.0001 and P<0.0001; Fig. 3A ) and mean fluorescence density (P<0.0001 and P<0.0001; Fig. 3B ) compared with those of the control group. As shown in Fig. 3C , 48 h after transfection, the relative TGFβ2 mRNA level in RPE-J cells of rAAV2-TGFβ2 shRNA-EGFP was markedly reduced compared with that of the control group and rAAV2-neg shRNA-EGFP group (P<0.0001 and P<0.0001). TGFβ2 gene silencing with a combination of US and rAAV2-TGFβ2 shRNA-EGFP resulted in a significant decrease in the mRNA expression level compared with the rAAV2-TGFβ2 shRNA-EGFP alone group (P<0.0001). TGFβ2 gene silencing with a combination of SonoVue and rAAV2-TGFβ2 shRNA-EGFP also resulted in a significant decrease in the mRNA expression level (P<0.0001). No significant difference was observed between the control group and the rAAV2-neg-shRNA-EGFP group (P>0.05). In addition, no 
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A B C significant difference was observed between the US group and the SonoVue group (P>0.05).
Discussion
The abnormal proliferation and migration of RPE cells play a crucial role in the onset and development of PVR (1) . Several studies have demonstrated that the inhibition of TGF-β has inhibitory effects on the proliferation of RPE, the formation of ECM and collagen contraction, and reduces the severity of PVR (11, 12) . These studies also suggest that targeting of the TGFβ2 gene with a siRNA in RPE cells has the potential to prevent the development of PVR.
Researchers have considered RPE cells to be a difficult cell type to transfect (13, 14) . Adeno-associated virus (AAV) vectors have a number of significant advantages over other vectors, in particular the ability to induce long-term transgene expression in the eye and a relative lack of pathogenicity. The identification of the AAV vector of RNAi provides the premise for enhanced use of RNAi technology to silence related genes in the treatment of ophthalmic diseases.
However, the transduction of AAV occurs with relatively low efficiency, which limits its therapeutic effects. Several methods to increase the transfection efficiency of AAV vectors have been explored, including combinational use with an adenovirus or a chemotherapy drug (7, 8) . However, the above strategies have a number of limitations. A new and improved method of delivery is required to improve AAV infection with enhanced performance in RPE cells.
In 1987, Fechheimer et al firstly proposed that US was able to promote gene transfection in vitro (15) . The mechanisms of US-mediated transfection or UTMD enhancing gene transfection are not clear. We performed a series of studies on UTMD enhancing gene transfection in RPE cells (data not shown), including various vectors (rAAV, plasmid, PEI, liposome), various genes (pDNA, siRNA) and various cell lines (RPE-J and ARPE19 cells). Moreover, we proved that UTMD could be used safely to enhance and accelerate rAAV2-EGFP transgene expression of the retina (9) . The goal of this feasibility study was to assess whether US and/or MBs could not only facilitate the delivery of rAAV2-EGFP but also downregulate TGFβ2 combined with rAAV2-TGFβ2 shRNA in rat RPE cells.
First, we observed the efficiency (ratio of positive cells) of UTMD combined with rAAV in driving transcription in RPE-J cells. The results reveal that US increased rAAV transfection efficiency. Under the conditions of 0.5 W/cm 2 and 30 sec, the increased transfection efficiency was significantly higher than that of other groups. Moreover, with an increase in US intensity and exposure time, the transfection efficiency and cell survival rate decreased. A 'window' of US intensity and exposure time exists and affects gene transfer efficiency. Higher or lower strength and longer or shorter exposure are not conducive to reaching the peak of gene transfer efficiency. With an increase in US intensity, the production probability of acoustic induced pores increased. With a long exposure time, the biological effect of cells increased, thereby affecting the cell survival rate. Under the conditions of 0.5 W/cm 2 and 30 sec, the energy was sufficient for the formation of transient pores in RPE-J cells and safe for cells.
The study demonstrated that rAAV combined with perfluoropropane-albumin microspheres without US was unable to increase rAAV transfection efficiency in RPE-J cells; however, SonoVue was able to do this. The differences in the two types of contrast agent were as follows: i) different composition of the membranes: lipid-shelled vs. albumin-shelled; ii) different components of wrapping gases: sulfur hexafluoride gas vs. perfluoropropane gas; iii) different size of microbubbles: 2.5-6.0 mm vs. 3-4.5 µm. We also used two types of MBs combined with rAAV-transfected ARPE19 cells, and neither SonoVue nor perfluoropropane-albumin microspheres had a positive effect (data not shown). RPE-J cells produced effective endocytosis of phospholipid membranes using SonoVue. There are few studies on the effect of different types of MBs on gene transfection efficiency. One study, comparing the effect of different microbubble contrast agents on gene transfection, demonstrated that Optison improved pDNA transfection efficiency in the skeletal muscle of mice, but SonoVue and Levovist did not (16) . The nonspecific phagocytic ability of cells may be the key factor in this notable phenomenon.
UTMD did not increase rAAV transfer to RPE-J cells but led to higher cell damage. MBs acting as cavitation nuclei effectively focus US energy and further potentiate bioeffects. Under UTMD conditions, the energy became too much for RPE-J cells and led to the high death rate of cells.
Whether US or MBs could damage RPE-J cells was also evaluated. With the increase in US intensity and exposure time, the survival rate of cells declined. High energy could lead to cell membrane fatigue, so that the corresponding position of the cell membrane damaged. Researchers have put most focus on whether US exposure or US combined with MBs affected the survival rate of cells. Few of them have paid attention to whether the US contrast agent itself caused cell damage. In our study, with the increase in MBs, the survival rate of cells declined. It is possible that the increase in MB concentration affected the living environment of the cell; for example, the osmotic pressure.
The combination of UTMD and rAAV should involve no destruction to the rAAV activity. Our previous study reveals that, under the UTMD conditions of intensity ≤3 W/cm 2 , exposure time ≤120 sec, MB:cell ratio ≤50:1, frequency 1 MHz, 50% duty cycle and pulse repetition frequency of 100 Hz, UTMD had no apparent effect on the transfection ability of rAAV (9) . Therefore, the parameters used in this study were safe for rAAV and cells.
The preconditions for the realization of RNAi are safe and efficient importation into the target cells, as well as long-term stable effect. The first part of our study proved that US or SonoVue facilitates rAAV delivery to RPE-J cells. The second part of the study aimed to prove that US or SonoVue could facilitate rAAV-TGFβ2 shRNA-EGFP delivery to RPE-J cells and downregulate the expression of TGFβ2 mRNA efficiently. The efficiency (ratio of positive cells and mean fluorescence density) of US or SonoVue combined with rAAV-TGFβ2 shRNA-EGFP was observed in driving transcription in RPE cells. US and SonoVue enhanced rAAV transfection efficiency by increasing the transgene expression per cell (an increase of 111.8 and 105.8%, respectively) and the percentage of transfected cells (an increase of 131.2 and 129.8%, respectively). Then RT-qPCR was performed to evaluate the relative TGF mRNA levels in the groups. It was observed that the enhanced TGFβ2 gene silencing under the condition of rAAV-TGFβ2 shRNA-EGFP combined with US or SonoVue resulted in a significant decrease in mRNA expression levels compared with rAAV-TGFβ2 shRNA treatment alone.
The mechanism by which rAAV delivery efficiency is enhanced by US and MBs is controversial (17, 18) . Only two public papers have been identified from PubMed research on this topic. One study suggested endocytosis as a mechanism that contributed to UTMD-enhanced AAV delivery (18) . The other indicated that US enabled direct entry of the AAV vectors into the cytoplasm (17) . In our study, SonoVue alone also enhanced AAV transfection and assisted in gene silencing. Although a study exists on the phenomenon (16) , there are no studies on the mechanism by which MBs alone enhance gene transfection efficiency. The mechanism by which rAAV delivery efficiency is enhanced in RPE-J cells by US or SonoVue is worthy of additional study.
In the present study, we demonstrated that low-intensity US or an appropriate dose of SonoVue could be used safely to increase the delivery efficiency of rAAV-TGFβ2 shRNA-EGFP to RPE-J cells. A combination of the biological (rAAV-TGFβ2 shRNA-EGFP) and physical (US) approaches could more effectively downregulate the mRNA expression of TGFβ2 than rAAV alone. RPE cells in vivo were pentagonal or hexagonal, and the morphology of RPE cells cultured in vitro was mainly spindle. When the cells were cultured in vitro, they lost neurohumoral regulation and the influence of adjacent cells, living in an environment with an absence of dynamic balance. Thus, the morphology and function would change to a certain extent. Further studies are required to evaluate whether the delivery of rAAV-TGFβ2 shRNA to RPE cells in a rat model of PVR may be enhanced by US and/or SonoVue.
